Moderna has announced that a Phase III trial of 'mRNA-1283', its new-generation Covid-19 vaccine currently under investigation, has met its primary efficacy endpoint, demonstrating non-inferior vaccine efficacy against COVID-19 compared with Spikevax.

The company also announced that efficacy was higher in adults aged 18 and over compared with Spikevax (mRNA-1273), with a consistent trend observed in the subgroup of adults aged 65 and over.

In the trial, mRNA-1283 showed a similar safety profile to Spikevax.

The company plans to present the Phase 3 clinical data for mRNA-1283 at an upcoming conference and submit them for publication. The company will also engage in discussions with regulators on the next steps in the program.




Copyright (c) 2024 CercleFinance.com. All rights reserved.